Sema4
Although the firm remains in the red, the new CEO is counting on testing volume growth, health system partnerships, and operational efficiencies including layoffs to reach profitability.
Sema4 Q1 Revenues Decline 16 Percent
The firm, which acquired GeneDx last month, recently cut its workforce by 10 percent as it charts a path to profitability.
In Brief This Week: FDA, Sema4, Veracyte, Trinity Biotech; Binx Health, More
News items for the in vitro diagnostics industry for the week of May 2, 2022.
Sema4 Q4 Revenues Decline 10 Percent
Sema4 beat the consensus Wall Street estimate on the top and bottom lines for Q4 and said it expects between $215 million and $225 million in revenues for 2022.
The purchase of GeneDx from Opko Health will help Sema4 accelerate its push into whole-exome sequencing and grow in rare disease diagnostics.
Jan 18, 2022
Sema4 to Acquire GeneDx for $623M
Jan 6, 2022
Nov 15, 2021
Sema4 Q3 Revenues Rise 12 Percent
Oct 8, 2021
BTIG Initiates Coverage of Sema4 With Buy Rating
Aug 16, 2021
Sema4 Reports 56 Percent Increase in Q2 Revenues
Jul 22, 2021
Jun 30, 2021
Jul 29, 2020
Sema4 Raises $121M in Series C Financing Round
Aug 29, 2019